section name header

Pronunciation

vil-AZ-oh-done

Classifications

Therapeutic Classification: antidepressants

Pharmacologic Classification: selective serotonin reuptake inhibitors ssris, benzofurans

Indications

BEERS REMS


Action

  • Increases serotonin activity in the CNS by inhibiting serotonin reuptake. Also binds selectively with high affinity to 5-HT1A receptors and is a 5-HT1A receptor partial agonist.
Therapeutic effects:

Pharmacokinetics

Absorption: 72% absorbed following oral administration with food.

Distribution: Unknown.

Protein Binding: 96–99%.

Metabolism/Excretion: Mostly metabolized by the liver, primarily by the CYP3A4 isoenzyme; 1% excreted unchanged in urine.

Half-Life: 25 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown4–5 hrunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Endo: SIADH

F and E: hyponatremia

GI: diarrhea, nausea, dry mouth, PANCREATITIS, vomiting

GU: libido, delayed/absent orgasm, ejaculatory delay/failure, erectile dysfunction

Hemat: BLEEDING

Neuro: insomnia, abnormal dreams, dizziness, NEUROLEPTIC MALIGNANT-LIKE SYNDROME, restlessness, SEIZURES, sleep paralysis, SUICIDAL THOUGHTS

Misc: SEROTONIN SYNDROME

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Viibryd